{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:33:16Z","timestamp":1792675996357,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":2333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s13311-017-0516-0","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T15:24:04Z","timestamp":1488813844000},"page":"333-344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":115,"title":["Oncolytic Virotherapy for the Treatment of Malignant Glioma"],"prefix":"10.1016","volume":"14","author":[{"given":"Paul M.","family":"Foreman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory K.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"Cassady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Markert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-017-0516-0_bib1","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1007\/s13311-017-0516-0_bib2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.nurt.2009.04.011","article-title":"Oncolytic viral therapy of malignant glioma","volume":"6","author":"Parker","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-017-0516-0_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-017-0516-0_bib4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/B978-0-12-802997-8.00011-6","article-title":"Experimental therapies: gene therapies and oncolytic viruses","volume":"134","author":"Hulou","year":"2016","journal-title":"Handb Clin Neurol"},{"key":"10.1007\/s13311-017-0516-0_bib5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"10.1007\/s13311-017-0516-0_bib6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"key":"10.1007\/s13311-017-0516-0_bib7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/neuonc\/not310","article-title":"Glioma virus therapies between bench and bedside","volume":"16","author":"Kaufmann","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1007\/s13311-017-0516-0_bib8","first-page":"82","article-title":"Sulla scomparsa di un enorme cancro vegetante del callo dell'utero senza cura chirurgica","author":"DePace","year":"1912","journal-title":"Ginecologia (France)"},{"key":"10.1007\/s13311-017-0516-0_bib9","first-page":"379","article-title":"Virus therapy in the treatment of tumors","volume":"12","author":"Higgins","year":"1951","journal-title":"Bull Hosp Joint Dis"},{"key":"10.1007\/s13311-017-0516-0_bib10","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/archderm.1950.01530180083015","article-title":"Note on the experimental use of rabies vaccine for melanomatosis","volume":"62","author":"Pack","year":"1950","journal-title":"AMA Arch Derm Syphilol"},{"key":"10.1007\/s13311-017-0516-0_bib11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(71)92086-1","article-title":"Regression of Burkitt's lymphoma in association with measles infection","volume":"2","author":"Bluming","year":"1971","journal-title":"Lancet"},{"key":"10.1007\/s13311-017-0516-0_bib12","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0140-6736(81)92286-8","article-title":"Regression of Hodgkin's disease after measles","volume":"1","author":"Taqi","year":"1981","journal-title":"Lancet"},{"key":"10.1007\/s13311-017-0516-0_bib13","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-017-0516-0_bib14","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/neuonc\/now002","article-title":"Phase 2 multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma","volume":"18","author":"Wheeler","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1007\/s13311-017-0516-0_bib15","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1126\/science.1851332","article-title":"Experimental therapy of human glioma by means of a genetically engineered virus mutant","volume":"252","author":"Martuza","year":"1991","journal-title":"Science"},{"key":"10.1007\/s13311-017-0516-0_bib16","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.gt.3301205","article-title":"Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial","volume":"7","author":"Markert","year":"2000","journal-title":"Gene Ther"},{"key":"10.1007\/s13311-017-0516-0_bib17","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.gt.3301184","article-title":"Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma","volume":"7","author":"Rampling","year":"2000","journal-title":"Gene Ther"},{"key":"10.1007\/s13311-017-0516-0_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/PPO.0b013e31824671c9","article-title":"Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates","volume":"18","author":"Wollmann","year":"2012","journal-title":"Cancer J"},{"key":"10.1007\/s13311-017-0516-0_bib19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1073\/pnas.94.3.843","volume":"94","author":"He","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-017-0516-0_bib20","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1172\/JCI116527","article-title":"Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models","volume":"91","author":"Whitley","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-017-0516-0_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0042-6822(88)90144-4","article-title":"Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant","volume":"166","author":"Goldstein","year":"1988","journal-title":"Virology"},{"key":"10.1007\/s13311-017-0516-0_bib22","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1128\/AAC.33.8.1395","article-title":"Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir","volume":"33","author":"Coen","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s13311-017-0516-0_bib23","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm0995-938","article-title":"Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas","volume":"1","author":"Mineta","year":"1995","journal-title":"Nat Med"},{"key":"10.1007\/s13311-017-0516-0_bib24","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1128\/JVI.73.8.6319-6326.1999","article-title":"Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates","volume":"73","author":"Hunter","year":"1999","journal-title":"J Virol"},{"key":"10.1007\/s13311-017-0516-0_bib25","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1128\/JVI.74.8.3832-3841.2000","article-title":"Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice","volume":"74","author":"Sundaresan","year":"2000","journal-title":"J Virol"},{"key":"10.1007\/s13311-017-0516-0_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/mt.2008.228","article-title":"Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM","volume":"17","author":"Markert","year":"2009","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-017-0516-0_bib27","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/mt.2014.22","article-title":"A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses","volume":"22","author":"Markert","year":"2014","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-017-0516-0_bib28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/sj.gt.3300546","article-title":"Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors","volume":"5","author":"Advani","year":"1998","journal-title":"Gene Ther"},{"key":"10.1007\/s13311-017-0516-0_bib29","first-page":"1517","article-title":"Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus","volume":"5","author":"Bradley","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-017-0516-0_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11060-009-9926-0","article-title":"Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111","volume":"95","author":"Friedman","year":"2009","journal-title":"J Neurooncol"},{"key":"10.1007\/s13311-017-0516-0_bib31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/neuonc\/nov123","article-title":"Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses","volume":"18","author":"Friedman","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1007\/s13311-017-0516-0_bib32","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/sj.gt.3301664","article-title":"The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study","volume":"9","author":"Papanastassiou","year":"2002","journal-title":"Gene Ther"},{"key":"10.1007\/s13311-017-0516-0_bib33","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/sj.gt.3302289","article-title":"HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival","volume":"11","author":"Harrow","year":"2004","journal-title":"Gene Ther"},{"key":"10.1007\/s13311-017-0516-0_bib34","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1073\/pnas.040557897","article-title":"Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors","volume":"97","author":"Parker","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-017-0516-0_bib35","first-page":"379","article-title":"The construction, selection, characterization, and application of recombinant herpes viruses","volume":"35","author":"Ackermann","year":"1988","journal-title":"Zentralbl Veterinarmed B"},{"key":"10.1007\/s13311-017-0516-0_bib36","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1073\/pnas.101136398","article-title":"Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing","volume":"98","author":"Todo","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-017-0516-0_bib37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0092-8674(89)90984-7","article-title":"Cellular targets for transformation by the adenovirus E1A proteins","volume":"56","author":"Whyte","year":"1989","journal-title":"Cell"},{"key":"10.1007\/s13311-017-0516-0_bib38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"10.1007\/s13311-017-0516-0_bib39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"key":"10.1007\/s13311-017-0516-0_bib40","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ccr.2004.11.012","article-title":"Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity","volume":"6","author":"O'Shea","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1007\/s13311-017-0516-0_bib41","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.ymthe.2004.07.021","article-title":"A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting","volume":"10","author":"Chiocca","year":"2004","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-017-0516-0_bib42","first-page":"1666","article-title":"Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus","volume":"23","author":"Xia","year":"2004","journal-title":"Ai Zheng"},{"key":"10.1007\/s13311-017-0516-0_bib43","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world's first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1007\/s13311-017-0516-0_bib44","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway","volume":"95","author":"Fueyo","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1007\/s13311-017-0516-0_bib45","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/gt.2008.98","article-title":"Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells","volume":"15","author":"Yokoyama","year":"2008","journal-title":"Gene Ther"},{"key":"10.1007\/s13311-017-0516-0_bib46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nec.2009.08.011","article-title":"Interferon-gamma in brain tumor immunotherapy","volume":"21","author":"Kane","year":"2010","journal-title":"Neurosurg Clin N Am"},{"key":"10.1007\/s13311-017-0516-0_bib47","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1093\/emboj\/17.12.3351","article-title":"The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus","volume":"17","author":"Strong","year":"1998","journal-title":"EMBO J"},{"key":"10.1007\/s13311-017-0516-0_bib48","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1073\/pnas.91.16.7727","article-title":"A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity","volume":"91","author":"Nishikawa","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-017-0516-0_bib49","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fonc.2014.00167","article-title":"Activated ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells","volume":"4","author":"Gong","year":"2014","journal-title":"Front Oncol"},{"key":"10.1007\/s13311-017-0516-0_bib50","doi-asserted-by":"crossref","first-page":"8561","DOI":"10.1158\/1078-0432.CCR-04-0940","article-title":"Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates","volume":"10","author":"Yang","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-017-0516-0_bib51","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.mt.6300403","article-title":"A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas","volume":"16","author":"Forsyth","year":"2008","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-017-0516-0_bib52","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/mt.2014.21","article-title":"Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults","volume":"22","author":"Kicielinski","year":"2014","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-017-0516-0_bib53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/cgt.2008.46","article-title":"An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors","volume":"16","author":"Lei","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"10.1007\/s13311-017-0516-0_bib54","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/03079457409353840","article-title":"Newcastle disease virus pathotypes","volume":"3","author":"Alexander","year":"1974","journal-title":"Avian Pathol"},{"key":"10.1007\/s13311-017-0516-0_bib55","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3181\/00379727-90-21945","article-title":"Propagation of Newcastle disease virus in Ehrlich ascites cells in vitro and in vivo","volume":"90","author":"Flanagan","year":"1955","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1007\/s13311-017-0516-0_bib56","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/jnci\/86.16.1228","article-title":"Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy","volume":"86","author":"Lorence","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1007\/s13311-017-0516-0_bib57","first-page":"6017","article-title":"Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy","volume":"54","author":"Lorence","year":"1994","journal-title":"Cancer Res"},{"key":"10.1007\/s13311-017-0516-0_bib58","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.281.17.1588-a","article-title":"Use of Newcastle disease virus vaccine (MTH-68\/H) in a patient with high-grade glioblastoma","volume":"281","author":"Csatary","year":"1999","journal-title":"JAMA"},{"key":"10.1007\/s13311-017-0516-0_bib59","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/B:NEON.0000021735.85511.05","article-title":"MTH-68\/H oncolytic viral treatment in human high-grade gliomas","volume":"67","author":"Csatary","year":"2004","journal-title":"J Neurooncol"},{"key":"10.1007\/s13311-017-0516-0_bib60","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1600-0463.2006.apm_516.x","article-title":"Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68\/H and oral valproic acid","volume":"114","author":"Wagner","year":"2006","journal-title":"APMIS"},{"key":"10.1007\/s13311-017-0516-0_bib61","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymthe.2005.08.016","article-title":"Phase I\/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme","volume":"13","author":"Freeman","year":"2006","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-017-0516-0_bib62","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/rmv.308","article-title":"The cellular receptor for measles virus\u2014elusive no more","volume":"11","author":"Yanagi","year":"2001","journal-title":"Rev Med Virol"},{"key":"10.1007\/s13311-017-0516-0_bib63","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0161-5890(99)00115-7","article-title":"Complement resistance of tumor cells: basal and induced mechanisms","volume":"36","author":"Jurianz","year":"1999","journal-title":"Mol Immunol"},{"key":"10.1007\/s13311-017-0516-0_bib64","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nm0502-527","article-title":"Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides","volume":"8","author":"Peng","year":"2002","journal-title":"Nat Med"},{"key":"10.1007\/s13311-017-0516-0_bib65","first-page":"2462","article-title":"Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme","volume":"63","author":"Phuong","year":"2003","journal-title":"Cancer Res"},{"key":"10.1007\/s13311-017-0516-0_bib66","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1089\/hum.2008.035","article-title":"Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I\/II clinical trial for patients with recurrent gliomas","volume":"19","author":"Myers","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1007\/s13311-017-0516-0_bib67","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1073\/pnas.93.6.2370","article-title":"Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants","volume":"93","author":"Gromeier","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-017-0516-0_bib68","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1073\/pnas.97.12.6803","article-title":"Intergeneric poliovirus recombinants for the treatment of malignant glioma","volume":"97","author":"Gromeier","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-017-0516-0_bib69","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1215\/S1152851703000577","article-title":"Poliovirus receptor CD155-targeted oncolysis of glioma","volume":"6","author":"Merrill","year":"2004","journal-title":"Neuro Oncol"},{"key":"10.1007\/s13311-017-0516-0_bib70","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2217\/fvl.11.76","article-title":"Oncolytic poliovirus against malignant glioma","volume":"6","author":"Goetz","year":"2011","journal-title":"Future Virol"},{"key":"10.1007\/s13311-017-0516-0_bib71","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/mt.2008.184","article-title":"Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype","volume":"16","author":"Dobrikova","year":"2008","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-017-0516-0_bib72","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1038\/mt.2013.207","article-title":"Panorama from the oncolytic virotherapy summit","volume":"21","author":"Pol","year":"2013","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-017-0516-0_bib73","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1439-0450.2005.00877.x","article-title":"Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review","volume":"52","author":"Geletneky","year":"2005","journal-title":"J Vet Med B Infect Dis Vet Public Health"},{"key":"10.1007\/s13311-017-0516-0_bib74","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cytogfr.2010.02.011","article-title":"Oncolytic parvoviruses as cancer therapeutics","volume":"21","author":"Rommelaere","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1007\/s13311-017-0516-0_bib75","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0166-0934(91)90024-T","article-title":"Antineoplastic activity of parvoviruses","volume":"33","author":"Rommelaere","year":"1991","journal-title":"J Virol Methods"},{"key":"10.1007\/s13311-017-0516-0_bib76","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ijc.11626","article-title":"Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing","volume":"109","author":"Herrero","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1007\/s13311-017-0516-0_bib77","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/neuonc\/noq023","article-title":"Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models","volume":"12","author":"Geletneky","year":"2010","journal-title":"Neuro Oncol"},{"key":"10.1007\/s13311-017-0516-0_bib78","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1471-2407-12-99","article-title":"Phase I\/IIa study of intratumoral\/intracerebral or intravenous\/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol","volume":"12","author":"Geletneky","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1007\/s13311-017-0516-0_bib79","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1586\/14737140.2015.1115725","article-title":"Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy","volume":"15","author":"Harrington","year":"2015","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-017-0516-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-017-0516-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-017-0516-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:06:55Z","timestamp":1761808015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923014691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1878747923014691"],"URL":"https:\/\/doi.org\/10.1007\/s13311-017-0516-0","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic Virotherapy for the Treatment of Malignant Glioma","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-017-0516-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}